mattmight

13 ms·

31.
by mattmight 6y ago
Bertrand's father here. I'm humbled to see his page show up on HN. HN was one of the sites that first picked up Bertrand's story years ago and it played a big role is several of the events that followed, such as when he was
32.
by mattmight 10y ago
I'm one of the paper authors. That's a great summary. Thanks! We're hopeful that this new algorithm already makes PwD practical enough for many use cases, and we have significant further improvements in progress. Stay tuned!
33.
by mattmight 11y ago
Not exactly: http://matt.might.net/articles/tenure/#addendum
34.
by mattmight 11y ago
It's in my talks, but not yet in a paper. I'm just about done writing a blog post on this topic too.
35.
by mattmight 11y ago
Olin (my advisor) deserved tenure on his strength as a teacher alone. (If tenure were awarded on such things anyway.) He also founded the entire field of static analysis for higher-order languages (like Scheme, Python and Haskell). His lo
36.
by mattmight 11y ago
Indeed, it is the story of a family, if you keep reading: http://matt.might.net/articles/tenure/#addendum And, in fact, an extended family story -- of my parents, my brothers and her sisters that all help out on a
37.
by mattmight 11y ago
Perhaps you didn't read the full reply before commenting: http://matt.might.net/articles/tenure/#addendum Maybe you don't consider founding and running a 501(c)(3) non-profit like http://NGLY1
38.
by mattmight 11y ago
As principal investigator for three of the listed DARPA projects (APAC, CRASH, STAC), I have to say that DARPA is by far my favorite research agency to work with. Every DARPA project I've worked on goes through the same three phases: 1
39.
by mattmight 11y ago
Yep! Jay McCarthy pointed this out, and I changed it. :)
40.
by mattmight 12y ago
Slides will be online, but I don't have plans to video record the lectures. A reasonable amount of the course material is in blog posts, and I add more posts each semester.
41.
by mattmight 12y ago
It stands from semester to semester. Typically, I create a fresh ubuntu server at the start of each semester, and I let it go unpatched for the duration of the semester.
42.
by mattmight 12y ago
At the moment, you'd have to enroll at the University of Utah. I might put the course online some day, but lectures are extremely interactive. I'm not sure how well they'll translate to an online format.
43.
by mattmight 12y ago
I'm looking forward to having you in the class!
44.
by mattmight 12y ago
I'll be updating the article at some point to add miniKanren. Will Byrd is my postdoc, and he's been pushing relational/logic programming with miniKanren: http://minikanren.org/ If you haven't seen miniK
45.
by mattmight 12y ago
Thanks for the kind words. The comment on jq (which I'd never seen) had me thinking about the relational shell programming again. One could implement a remarkably robust relational DB at the shell with jq.
46.
by mattmight 12y ago
There's one German patient, but no one has reached out recently from Germany. Can you point me to the site?
47.
by mattmight 12y ago
You may want to check out LineaGen: http://www.lineagen.com/ It's cheaper than sequencing, and more importantly, they actually know what to do with the data once they have it. Getting your sequencing data is becoming c
48.
by mattmight 12y ago
There's no doubt that my technical blog helped do this the first time. But, I firmly believed that this could be repeated without an established presence. And, it has been repeated. After I co-authored an article with a fellow parent
49.
by mattmight 12y ago
Hi Hiren! Thanks again for meeting with me after the original post! Please send me a link to the pages once they're up. What you're doing is really critical. I've discovered that a lot of non-glycobiologists 'shut down&
50.
by mattmight 12y ago
Sanford Burnham is in San Diego and is the leading lab for NGLY1. All of the cell lines for all of the patients are there. Dr. Freeze has a variety of assays related to NGLY1 available. We'll get you access ASAP. I'll be in to
51.
by mattmight 12y ago
Holy shit, you're in the zone! We'd been considering N-acetyl-dideoxy-nojirimycin (2-ADN) to inhibit a different enzyme related to NGLY1. (I can't discuss more publicly since the research is unpublished, but would be happy t
52.
by mattmight 12y ago
I wish you and your wife much luck. If the docs at NIH come back with a pile of variants of unknown clinical significance, get in touch with me. I'll help you find patient #2.
53.
by mattmight 12y ago
Thanks for the kind words and the nod, but I can assure you that there's still no shortages of excuses for late homework. Since this is HN, I'll share one thing that works: force your students to use git (or some version control)
54.
by mattmight 12y ago
Of course we've considered it. It's a murky moral calculus.
55.
by mattmight 12y ago
There is no such web site. I've advised another family on how to repeat our success, and they managed to find a second patient by setting up a website for their child. Both kids had de novo mutations in KDM1A and could be mistaken for
56.
by mattmight 12y ago
Thanks for the kind words. If you had told me when my son was born that we'd have to discover a disease as just the first (small) step toward saving him, we would have crumbled. We weren't ready for what had to be done. But, paren
57.
by mattmight 12y ago
CF has popped up more than once when looking at treatments for NGLY1. In fact, the first ever treatment we tested in the lab was a read-through compound often used to treat some forms of CF: gentamycin. It didn't work for Bertrand, but
58.
by mattmight 12y ago
We're up against this right now for NGLY1. There's a compound in trials right now that has shown tremendous promise in my son's cells in the lab and in the cells of other NGLY1 patients. But, we can't get permission to g
59.
by mattmight 12y ago
Thank you!
60.
by mattmight 12y ago
We can, but we're not very good at it (yet): https://en.wikipedia.org/wiki/Gene_therapy I've been speaking with gene therapy researchers, and they do believe that NGLY1 is a good candidate for gene therapy be

More ›